We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

MedXY Editorial Team•Dec 9, 2025•Cardiology
cardiogenic shockVA-ECMO

Highlight

– The LEVOECMO randomized, double‑blind trial (n=205) found no reduction in time to successful VA‑ECMO weaning with early levosimendan versus placebo.
– Successful weaning at 30 days occurred in 68.3% of patients in both groups; subdistribution hazard ratio 1.02 (95% CI, 0.74–1.39; P = .92).
– Secondary outcomes including ECMO duration, ICU length of stay, and 60‑day mortality were similar; ventricular arrhythmias were more frequent with levosimendan.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Reducing Mortality in Cardiogenic Shock: The Impact of Hospital Capability and Transfer StrategiesHigher hospital cardiac capability correlates with lower mortality in cardiogenic shock patients, and regionalized hub-and-spoke models mitigate the transfer penalty associated with patient instability.Sep 19, 2026Impact of Geographic Access on Mortality in Cardiogenic Shock: Insights from a Nationwide Korean CohortLonger hospital arrival times significantly increase both in-hospital and long-term mortality in cardiogenic shock, highlighting the urgent need for regional care coordination and early triage.Sep 5, 2026Impact of Geographic Access on Mortality in Cardiogenic Shock: Insights from a Nationwide Korean CohortA nationwide South Korean study reveals that longer hospital arrival times significantly increase both in-hospital and long-term mortality in patients with cardiogenic shock, emphasizing the need for improved regional healthcare coordinatioSep 3, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Cardiogenic Shock Care Still Varies Widely Across CICUs, Especially in the Choice of Inodilators
A large CCCTN analysis found major institutional and patient-level variation in vasoactive drug selection for cardiogenic shock, highlighting persistent evidence gaps in choosing dobutamine, milrinone, and other vasoactive therapies.
May 19, 2026
Circulatory Support Escalation in Cardiogenic Shock: Outcomes and Predictors of SuccessA multi-center study reveals that circulatory support escalation in cardiogenic shock is associated with higher mortality and complications, but certain patient factors can predict successful outcomes.Apr 28, 2026
Transfer Before Support: Why Cardiogenic Shock Patients Referred from Regional Centers Face Higher Device-Related ComplicationsA large observational study reveals that cardiogenic shock patients receiving temporary mechanical circulatory support at regional referral centers before transfer to hub centers experience significantly higher device-related adverse eventsApr 15, 2026